HB 254, titled the “New Hampshire End of Life Freedom Act,” would create a new chapter in state law authorizing medical aid in dying for certain terminally ill adults. The bill sets out a detailed process for eligibility, including that the person must be an adult with mental capacity, have a terminal condition with a prognosis of six months or less to live (or be enrolled in Medicare-certified hospice), voluntarily request the medication, and be able to self-administer it. It requires confirmation by an attending health care provider and a consulting health care provider, informed-consent disclosures, witness signatures, a 48-hour waiting period in most cases, and referral to a mental health professional if capacity is in doubt.
The bill also establishes rules for provider conduct, record transfer, reporting, and post-death handling. It creates immunity for providers and others acting in good faith under the chapter, while also protecting conscience-based refusals by providers and health care entities. At the same time, it prohibits coercion, forgery, concealment, or interference with a request or prescription and makes certain violations a class B felony. The Department of Health and Human Services would collect data and publish an annual statistical report, and the bill specifies that deaths under the act are attributed to the underlying terminal disease rather than suicide or homicide.
In terms of state law impact, HB 254 would add a new statutory framework governing end-of-life medication, affecting health care providers, pharmacies, hospices, insurers, health care entities, coroners, and the Department of Health and Human Services. It would also alter how death certificates are completed, how insurance and annuity policies may treat a person’s request for aid in dying, and how contracts or wills may be used to limit or condition access to the process. The fiscal note anticipates minimal direct administrative costs for DHHS, but notes possible indeterminate effects on insurance premium tax revenue and potential judicial and correctional costs from the new criminal penalties.
The general sentiment reflected in the available history is sharply divided. The bill was tabled in the House by a very narrow margin, 183-182, indicating substantial support but also substantial opposition. No committee transcript excerpts were provided, but the close vote suggests the measure is highly controversial and likely to have drawn strong views on both personal autonomy and end-of-life choice versus concerns about the ethics and safeguards of medical aid in dying.
The main points of contention are likely to center on whether the state should authorize physician-assisted death at all, whether the bill’s safeguards are sufficient to prevent coercion or misuse, and how conscience protections for providers and institutions should be balanced against patient access. Additional likely concerns include the role of hospice and Medicare eligibility, the scope of immunity and criminal penalties, and whether the bill’s treatment of death certificates, insurance, and institutional policies appropriately protects patients, families, and health care workers.
HB 254 would create a new chapter in the RSA establishing legal procedures for medical aid in dying, thereby changing the duties and liabilities of physicians, advanced practice registered nurses, pharmacists, health care entities, insurers, and state agencies. It would require DHHS rulemaking and annual reporting, impose new documentation and disclosure requirements, and add criminal penalties for interference or coercion. The bill would also affect insurance law, contract enforceability, and death-certificate practices, while explicitly limiting the use of the act to competent adults with terminal illness who can self-administer the medication.
The bill appears to have generated strong and polarized reactions. The House vote to table it by only one vote, 183-182, indicates that support and opposition were nearly evenly split. That close result suggests meaningful backing for end-of-life autonomy, but also significant concern about the moral, medical, and legal implications of authorizing medical aid in dying.
The central dispute is whether New Hampshire should permit medical aid in dying for terminally ill adults and, if so, whether the bill’s safeguards are adequate. Supporters are likely focused on patient autonomy, relief from suffering, and the ability of mentally capable adults to choose a peaceful death. Opponents are likely concerned about coercion, the role of physicians in prescribing lethal medication, and the possibility of pressure on vulnerable patients. Additional contention arises from the bill’s conscience protections for providers and institutions, its criminal penalties for interference, and its rules affecting insurers, hospice settings, and institutional policies.